Latest News and Press Releases

SB12（即AMT904）是依库珠单抗生物仿制药的候选药物，用于治疗阵发性夜间血红蛋白尿唯一获得中国新药临床研究批准的舒立瑞®（依库珠单抗）1的生物仿制药候选药物 韩国仁川和中国上海, Jan. 10, 2020 (GLOBE NEWSWIRE) --  Samsung Bioepis和AffaMed...

SB12 (also referred to as AMT904) is an eculizumab biosimilar candidate for the treatment of paroxysmal nocturnal hemoglobinuria The only biosimilar candidate referencing Soliris® (eculizumab)1 to be...

SHANGHAI, China, Dec. 10, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a biopharmaceutical company founded and funded by CBC Group, a healthcare private equity firm focused on the development and...

中国上海, Dec. 10, 2019 (GLOBE NEWSWIRE) -- 由专注于医疗行业成长期和后期阶段投资机会的私募股权投资基金CBC Group出资成立的生物制药公司AffaMed...

SHANGHAI, China, Dec. 10, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a biopharmaceutical company founded and funded by CBC Group, a healthcare private equity firm focused on the development and...

紐約, Nov. 12, 2019 (GLOBE NEWSWIRE) -- CBC Group 是一家私募股權公司，專注全球醫療保健市場的育成、收購和後期增長投資機會，今天宣佈委任行業資深人士 Kerry Blanchard (PhD, MD) 為營運合夥人。Blanchard 博士將在此職位上支援 CBC Group 投資組合公司管理團隊執行其價值創造計劃。 CBC Group 行政總裁...

NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- CBC Group, a private equity firm focused on incubation, buyout and late-stage growth investment opportunities within the global healthcare market,...

上海和纽约, May 10, 2019 (GLOBE NEWSWIRE) -- Everest Medicines今天宣布任命制药行业资深人士陈文德先生为其首席商务官。Everest Medicines 是一家专注于针对大中华及亚洲其它地区的患者之医疗需求的生物制药研发及商业化公司。在担任首席商务官的同时，陈文德也将担任康桥资本（CBC Group，前英文名C-Bridge...

SHANGHAI, China and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that...

中國上海, Feb. 13, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics為一間新的生物製藥公司，由C-Bridge Capital出資成立。C-Bridge Capital是一間醫療行業的私人股本公司，專注於成長期和後期階段的投資機會。AffaMed Therapeutics今天宣佈與Samsung...